32 results about "Insulin Cell" patented technology

The invention relates to an enteric material coated chitosan nanoparticle which covers insulin and cell-penetrating peptide Tat and a preparation method of the chitosan nanoparticle. The chitosan nanoparticle is prepared from an enteric material, namely Eudragit S100, insulin, cell-penetrating peptide and chitosan. With the oral administration of the prepared enteric coated insulin chitosan nanoparticle, the amount of loaded contents released from the chitosan nanoparticle in the stomach and the upper part of the small intestine can be greatly reduced due to the protective effect of the enteric material, namely Eudragit S100. As the chitosan nanoparticle arrives at the lower end of the digestive tract, the enteric coating material on the surface of the chitosan nanoparticle begins to dissolve and the chitosan nanoparticle becomes exposed with the increase of pH value; the chitosan nanoparticle is damaged under a weakly alkaline condition, so that the cell-penetrating peptide and the insulin therein are released. The cell-penetrating peptide is capable of prompting the absorption of colonic epithelial cells to the insulin so as to improve the bioavailability of the insulin through oral administration.

The invention discloses a method for constructing tissue engineering islet by adipose derived mesenchymal stem cells and the obtained tissue engineering islet. The method employs adipose derived mesenchymal stem cells with extensive sources to perform culture on islet acellular matrix, so that the acellular matrix can provide a three-dimensional space suitable for growth to adipose derived mesenchymal stem cells so as to promote cell adhesion, proliferation and differentiation, and formation of a three-dimensional structure engineering islet tissue able to stably secrete insulin. The method realizes gathering of insulin secreting cells, enhances cell utilization and is expected to promote the effect of repairing islet injury by tissue engineering method.

A balsam pear buccal tablet takes balsam pear powder as the major ingredient and American ginseng saponin and mannite as accessories; wherein the weight percent of the ingredients is: 50-55 percent of balsam pear powder, 25-30 percent of American ginseng saponin and residual amount of mannite. The preparation comprises the following steps: 1) selecting high-quality fresh balsam pear as the raw material, dehydrating the fresh balsam pear by low temperature technology and preparing into balsam pear powder; 2) uniformly mixing the powder material based on the weight percent of the ingredients; 3) pressing the powder into tablets by the conventional method, packing or filling hermetically. The balsam pear buccal tablet has the advantage that, in the balsam pear buccal tablet prepared by the method, the hypoglycemic peptide in the main raw material--balsam pear, has the efficacy of reducing blood sugar safely and stably, improving the function of pancreas, increasing the activity of insulin cells of human body, improving the capability of regulating blood sugar, regulating blood fat and lowering blood pressure. Furthermore, the bitter principle in the balsam pear can stimulate the secretion of salivary gland to increase, better relive the symptoms of dry mouth and thirst of diabetics. The balsam pear buccal tablet is easy to eat, which is a pure natural healthcare product.

The invention discloses a traditional Chinese medicine composition for treating diabetes and a method for preparing the same, which belong to the field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared by the following materials in weight portion: 30 to 50 portions of milkvetch root, 15 to 30 portions of yam, 15 to 20 portions of atractylodes rhizome, 30 to 50 portions of figwort root, 30 to 50 portions of red sange root, 15 to 20 portions of kudzuvine root, 15 to 20 portions of prepared rehmannia root and 10 to 15 portions of cornel. According to the general preparation method of traditional Chinese medicines, the traditional Chinese medicine composition can be prepared to be any preparation formulation suitable for clinical application. The traditional Chinese medicine composition has functions of improving the immunity of a patient, improving the insulin secretion of insulin cells of the patient, reducing the volume of fat cells and relatively increasing the number of insulin receptors on cell membranes, has the efficacies of reducing blood sugar and build up body, and has the advantages of quick treatment effect, good curative effect and the like for treating diabetes.

The invention discloses a method for inducing an umbilical cord mesenchymal stem cell to differentiate to form insulin. The method comprises the following steps: separating and cultivating the umbilical cord mesenchymal stem cell in vitro; enabling a cell factor to induce the umbilical cord mesenchymal stem cell to differentiate into an insulin cell: inoculating a third generation umbilical cord mesenchymal stem cell in a culture flask T25cm, adding an inducing liquid when the cell is fused by 80%-90%, and inducing the cell to obtain the insulin cell. The differentiating capability of the umbilical cord mesenchymal stem cell obtained by separating and cultivating umbilical cord blood is relatively strong, and the umbilical cord mesenchymal stem cell has a multi-directional differentiation potential, supports hematopoiesis and has an immunosuppression effect. Compared with donating bone marrow or drawing and mobilizing peripheral blood, a donator has no pain, the risk of infection is reduced, and the amplification capability is strong.

The buckwheat-spirulina tablet is prepared with spirulina 85.0-92.5 wt%, buckwheat extract 5.0-10.0 wt%, cellulose 1.0-2.0 wt%, silica 1.25-2.5 wt% and magnesium stearate 0.25-0.5 wt%. The preparation process includes crushing spirulina and buckwheat extract, 40-60 mesh sieving, mixing with other ingredients, sieving and tabletting in a rotary tabletting machine. It has the nutritious components of spirulina and bioactive components of buckwheat, and contains 55 wt% over high quality protein, amino acids, etc essential for human body. It can replenish balanced nutrients, strengthen bodyí»s activity, promote the recovery of insulin cell, improve sugar tolerance, lower blood viscosity and capillary blood vessel brittleness, lower blood sugar and blood fat, and promote blood circulation.

The invention discloses a plant solid beverage and belongs to the technical field of health-care food. The plant solid beverage is produced from, by weight, 10-20 parts of rhizoma dioscoreae, 10-20 parts of rhizoma polygonati, 5-15 parts of folium mori powder, 5-15 parts of pollen pini, 3-8 parts of oat beta-glucan, 3-8 parts of ginseng, 3-8 parts of cortex cinnamomi, 3-8 parts of fructus lycii, 3-8 parts of fructus hippophae, 3-8 parts of radix pueraiae, 3-8 parts of bitter gourd, 3-8 parts of okra, 3-8 parts of glucose-based stevioside and 3-8 parts of mogroside. The compound plant solid beverage has the advantages that the compound plant solid beverage is produced from medicinal and edible traditional Chinese medicine materials and functional auxiliary materials, the mutual influence and interaction of the components allow the compound plant solid beverage to provide comprehensive nutritional support for diabetics, comprehensively supplement nutrients needed by human body cells andincrease insulin cell activity and body resistance, and the plant solid beverage can fast repair damaged blood vessel cells and regulate the intestines and the stomach.

The invention discloses a diet food for reducing blood sugar. The diet food comprises the following raw materials in parts by weight: 18-30 parts of black wood ears, 15-23 parts of bitter gourds, 8-15 parts of Chinese yams, 13-17 parts of laver, 10-25 parts of carrots and 13-18 parts of garlic. The diet food disclosed by the invention is easy to absorb by human bodies, high in nutrient value, natural and free from side effects; and the adopted raw materials contain rich cellulose and important components for reducing blood sugar, so that the diet food can alleviate the decomposition and the absorption of carbohydrate, has the efficacies of reducing blood pressure, protecting islet cells, regulating blood sugar, reducing blood sugar, and improving the immunity of human bodies, and does not have contraindications when being eaten for a long term.

An implantable pouch and methods for implanting cells or cellular matter in mammals, comprising reinforced porous foam and a lumen. The lumen contains an insert that may or may not be removed prior to transplantation. The lumen may be loaded with at least one cell type expressing at least one transcription factor characteristic of a mammalian pancreatic beta cell.

The present invention discloses a use of dipeptidyl peptidase-IV inhibitor in producing a medicine which is used for long-term oral medicine taking for preventing Type II Diabetes in mammal, wherein the peptidase-IV inhibitor converts the cells in pancreas to cells generating insulin, so that the pancreatic cell proliferate to functional active islet cells and / or the insensitive or damaged pancreatic cells convert to functional active islet cells.

The invention discloses a bitter gourd powder solid beverage and a preparation technology thereof. The beverage comprises the following raw material components of 15-25% of bitter gourd powder, 20-35%of oolong instant tea powder, 15-23% of inulin, 8-12% of haw powder, 8-12% of ground cinnamon, 8-15% of fructus momordicae powder, and 11-13% of xylitol. The preparation technology is simple, and theprepared beverage has the effects of regulating blood lipid and reducing blood pressure, can enable the activity of insulin cells to be strengthened, the autogenous regulation capacity for blood sugar to be strengthened, and the oxidation of blood sugar to be accelerated, conforms to nature metabolism law of human bodies, can prevent and improve the complication of diabetes, and has the effect ofregulating the blood fat and improving the immunity.

The invention aims to provide a traditional Chinese medicine for treatment of diabetes. The traditional Chinese medicine is prepared from the following bulk drugs by weight: 2-8 parts of Dendrobium, 6-10 parts of ophiopogon japonicas, 2-7 parts of Codonopsis pilosula, 6-10 parts of Chinese yam, 8-15 parts of Coptis chinensis, 3-8 parts of corn stigma, 4-10 parts of radix rehmanniae, 10-16 parts of polygonatum odoratum, 2-10 parts of chicken's gizzard-membrane, 3-10 parts of cornus officinalis, 2-6 parts of Cortex Lycii, 1-5 parts of kudzu vine root, 6-10 parts of astragalus, 8-18 parts of atractylodes lancea, and 6-10 parts of Radix Trichosanthis. The traditional Chinese medicine for treatment of diabetes provided by the invention conditions the human body through specific pharmacological properties, enhances immunity, restores insulin cell functions, declines blood glucose smoothly, and has significant effect. The traditional Chinese medicine provided by the invention has the advantages of reliable efficacy, small side effect, convenient treatment and difficult relapse, and can gradually cure diabetes by continuous taking.

The invention discloses traditional Chinese medicine for treating diabetes. Huidouba and guava leaves as used as main components, and components including cinnamomum cassia, Chinese yam rhizome, dictyophora indusiata, astragalus membranaceus and the like are mixed into the main components for preparing the traditional Chinese medicine. The traditional Chinese medicine is prepared from the following components in a recipe in percentage by weight: 2 percent to 7 percent of dictyophora indusiata, 2 percent to 5 percent of cinnamomum cassia, 9 percent to 15 percent of gardenia, 8 percent to 15 percent of guava leaves, 5 percent to 15 percent of zaocys dhumnade, 5 percent to 8 percent of angelica dahurica, 3 percent to 9 percent of fructus citri, 10 percent to 16 percent of Huidouba, 8 percent to 20 percent of Chinese yam rhizome, 5 percent to 10 percent of kudzu root leaves, 8 percent to 12 percent of astragalus membranaceus and 4 percent to 10 percent of corn stigma. During the medicine taking, firstly, the Huidouba is treated through micro washing and is then mixed with other components; after the components are decocted and boiled for 20 minutes in an earthen pot, liquid is taken; one dose is taken every day in 2 to 3 times; or the Huidouba is treated through micro washing and is then boiled to the boiling state for 15 minutes in the earthen pot; and the liquid is taken; and the rest medicine is made into pills or granules to be taken at the same time. The traditional Chinese medicine composition has the main function of controlling, relieving and treating the diabetes; the curative effect taking speed is high; and the diabetes cannot easily reoccur. The traditional Chinese medicine has low dependency and small toxic or side effects; the aging of insulin cells can be reduced; and the induction of various inductions can be prevented.

The invention relates to the field of health drinks, and aims to provide hypertension, hyperlipidemia and hyperglycemia reducing health care milk tea and a preparation method thereof. The formula comprises the following raw materials by weight: 25-33 parts of Pu'er tea, 2-4 parts of scutellaria baicalensis, 1-3 parts of astragalus membranaceus, 3-5 parts of pueraria, 2-5 parts of hawthorn, 2-4 parts of semen cassiae, 4-9 parts of vitamin C, 45-53 parts of skim milk powder and 700-970 parts of deionized water. The hypertension, hyperlipidemia and hyperglycemia reducing health care milk tea has the beneficial effects that: the hypertension, hyperlipidemia and hyperglycemia reducing health care milk tea can significantly enhance the effect of inhibition of increase of the content of cholesterol and triglyceride which are main blood fat components in the body, can promote discharge of lipid compounds from faeces, and can increase the capillary wall elasticity, therefore the hypertension, hyperlipidemia and hyperglycemia reducing health care milk tea plays an important role in prevention and cure of atherosclerosis, hypertension and obesity, can significantly stimulate sensitivity and activity of insulin cells, and has obvious effect on decreasing blood glucose.

The invention provides a grain composition for improving blood glucose. The grain composition provides dietary fibers, proteins, carbohydrates, vitamins and minerals for the human body through all thecomponents, and thereby nutritional requirements of the human body are balanced. In the grain composition, sesame seed, corn flour, tartary buckwheat, red bean, white hyacinth bean and other grains can provide carbohydrates for the human body, concentrated whey protein powder, milk powder, sea cucumber powder, soybean protein isolate powder and the like can provide protein sources for the human body, and sufficient and rich vitamins and minerals can be provided for the human body through the interaction of all the components. Effective substances, namely total flavonoids and biological polysaccharides with biological activity, contained in all the components can take auxiliary blood glucose reduction as an entry point to act together to reduce the absorption of carbohydrates and fat by the organism, reduce fasting blood glucose concentration, improve functions of islet cells, increase the sensitivity of insulin cells and the reserve of liver glycogen, lower the blood glucose level, prevent the excessive increase of postprandial blood glucose, improve glucose tolerance, and stabilize human blood glucose.

The invention discloses a natural product Loureirin B analogue as well as a preparation method and application thereof. The structure of the compound is shown in the specification. The preparation method of the natural product Loureirin B analogue is characterized in that 2,4-dimethoxybenzaldehyde and 1-(2,4-di(benzyloxy)phenyl)ethyl-1-ketone are used as starting materials, and aldol condensationand catalytic hydrogenation reaction are performed to obtain the natural product Loureirin B analogue. The preparation method has the advantages that the quality control is easy to carry out, massivepreparation can be realized, and the cost is low. The compound has an excretion promoting effect on insulin cells, and can be used for preparing candidate medicines for treating hyperglycemia. The method is simple and easy to implement, low in cost and suitable for application and popularization.

The invention discloses a traditional Chinese medicine for treating type 2 diabetes, and relates to a traditional Chinese medicine. The traditional Chinese medicine for treating the type 2 diabetes is characterized by consisting of the following Chinese herbal medicines in parts by weight: 10-60 parts of root of fragaria vesca, 15-60 parts of root of common embelia fruit, 20-60 parts of root of patent hairy melastoma, 10-50 parts of pollen, 10-60 parts of pueraria mirifica, 20-90 parts of vines and leaves of ipomoea batatas and 10-30 parts of guava leaf. The traditional Chinese medicine disclosed by the invention has the advantages of regulating function balance of a human body, regulating an internal environment, relieving insulin resistance, recovering insulin cell functions and eliminating functional defect of bioactive substances so as to promote the recovery of glucose and metabolism functions of the human body.

The invention discloses a formulated Chinese medicine for curing diabetes, which belongs to the field of traditional Chinese medicine. It is prepared from: 30-35g of waxgourd peel, 19-21g of balsam pear, 16-18g of beggarticks, 19-21g of cogongrass rhizome, 19-21g of purslane, 19-21g of loach, 20-24g of mantis egg-case, 18-20g of acanthopanax senticosus, 23-28g of radix scutellariae, 19-21g of scrophularia, 19-21g of rhizoma anemarrhenae, 15-19g of radix trichosanthis, 19-21g of cortex lycii, 14-17g of poria, 19-21g of galla chinensis, 16-18g of rhizoma polygoni cuspidati, 20-23g of dioscorea opposita thunb, 19-21g of pueraria lobata, 22-28g of root of wild kiwis, 28-32g of ganoderma lucidum and 16-19g of silkworm cocoon. This medicine cures diabetes through reducing blood sugar and recuperating, which has been certified to have no toxic side effect by clinic tests. This invention has a significant hypoglycemic effect while recuperating the internal, supplementing qi and nourishing yin, gradually repairing the insulin cells and recovering one's health.

The invention relates to a chitosan nanoparticle coated with an enteric-coated material and wrapped with insulin and a cell-penetrating peptide Tat and a preparation method thereof. prepared from chitosan. After oral administration of the prepared enteric-coated insulin-chitosan nanoparticles, the protective effect of the enteric-coated material Eudragit S100 can greatly reduce the release of the loaded contents of the chitosan nanoparticles in the stomach and upper small intestine. quantity. When the chitosan nanoparticles reach the lower end of the digestive tract, due to the rise of the pH value, the enteric coating material on the surface of the chitosan nanoparticles begins to dissolve and expose the chitosan nanoparticles. It is destroyed under certain conditions, thereby releasing the cell-penetrating peptide and insulin inside. Cell-penetrating peptides promote the absorption of insulin by colonic epithelial cells, thereby increasing the oral bioavailability of insulin.

The invention discloses a traditional Chinese medicine composition for treating diabetes and a method for preparing the same, which belong to the field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared by the following materials in weight portion: 30 to 50 portions of milkvetch root, 15 to 30 portions of yam, 15 to 20 portions of atractylodes rhizome, 30 to50 portions of figwort root, 30 to 50 portions of red sange root, 15 to 20 portions of kudzuvine root, 15 to 20 portions of prepared rehmannia root and 10 to 15 portions of cornel. According to the general preparation method of traditional Chinese medicines, the traditional Chinese medicine composition can be prepared to be any preparation formulation suitable for clinical application. The traditional Chinese medicine composition has functions of improving the immunity of a patient, improving the insulin secretion of insulin cells of the patient, reducing the volume of fat cells and relatively increasing the number of insulin receptors on cell membranes, has the efficacies of reducing blood sugar and build up body, and has the advantages of quick treatment effect, good curative effect andthe like for treating diabetes.

The composition of Chinese medicine for curing diabetes is formed from (by weight ratio) scutellaria root 3-10, phellodendron bark 3-12, astragalus root 8-12, red ginseng 5-10, dried / fresh rehmannia root 10-18 and poria 7-14. Said invented Chinese medicine can completely regulate magnesium of human body, balance internal yin and yang, improve qi and blood distribance, recover functions of internal organs, strengthen kidney and fortify spleen and can promote islet cell to normally secrete insulin so as to obtain the goal of curing diabetes.

The present invention relates to a method of predicting the response of a type 1 diabetes patient to a treatment with an immunogenic peptide comprising an insulin MHC II T cell epitope and an oxidoreductase motif, comprising determining the MHC class II HLA haplotype of the patient.

The present invention discloses a method for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic ²-cells and to cause differentiation of pancreatic epithelial cells into insulin producing ²-cells. Oral administration of a DP-IV inhibitor causes the active form of GLP-1 to be preserved longer under physiological conditions. The extended presence of GLP-1, in particular in the pancreatic tissue facilitates differentiation and regeneration of the ²-cells already present that arc in need of repair. These repaired insulin producing cells can contribute to the correction and maintenance of normal physiological glycemic levels.

On the basis of studies on influence the sodium arsenite on the synthesis and secretion of insulin in pancreatic beta cells, the invention provides an optimized dosage of the sodium arsenite for promoting the synthesis and the secretion of the insulin in the pancreatic beta cells. The optimized dosage of the sodium arsenite for promoting the synthesis and the secretion of the insulin in the pancreatic beta cells is obtained from various experiments, so that the unhelpful influence of arsenic in conventional dosages on human body is changed; the proliferation of insulin cells is promoted by controlling the amount of the sodium arsenite, and the number of the insulin cells is directly linked to the treatment of such diseases as diabetics; therefore, the invention has a relatively important value on the study.

An implantable pouch and methods for implanting cells or cellular matter in mammals, comprising reinforced porous foam and a lumen. The lumen contains an insert that may or may not be removed prior to transplantation. The lumen may be loaded with at least one cell type expressing at least one transcription factor characteristic of a mammalian pancreatic beta cell.

The invention relates to a tea beverage capable of cooling blood, removing toxins and reducing blood glucose and a preparation method thereof. The tea beverage is prepared from, by weight, 25-35 g of milkvetch roots, 8-12 g of mulberry bark, 8-12 g of mulberry leaves, 8-12 g of black tartary buckwheat straw, 5-10 g of black tartary buckwheat rice, 4-7g of wild seven-leaf gynostemma pentaphylla tendrils, 4-7 g of Tibet wild green bonnie flowers and 4-7 g of Tibet wild green bonnie flower stalks. Under the combined action of several ingredients of milkvetch roots, mulberry trees, tartary buckwheat, gynostemma pentaphylla and the Tibet wild green bonnie flowers, the tea beverage can more effectively activate the blood, cool the blood, dissipate heat, remove the toxins, activate a self-healing system of the human body, activate and regenerate insulin cells needed by the human body and promote glucose conversion, is free of side effects, suitable for people of all ages and free of restrictions and not regaining for a long time after the tea stops being drunk and really achieves the purposes of quickly reducing blood glucose and radically treating various types of diabetics symptoms.

The invention provides a medicament for treating diabetes and a preparation method of the medicament, which are used for overcoming the defects of the conventional medicaments for treating diabetes. The medicament for treating diabetes comprises a concentrated extract of a natural plant, i.e., salacia oblonga, original powder of kudzu, original powder of ginseng and original powder of bitter gourd. The medicament has the beneficial effects that: an action can be played from the source of diabetes, and the entrance of sugars into cells is controlled effectively, so that the blood sugar level in blood is controlled, the condition of a patient suffering from diabetes is relieved, and the patient's condition is prevented from being deteriorated; the reactions of insulin cells can be more sensitive, the total amount of needed insulin is reduced, and substances which are unbeneficial to pancreas cells are removed, so that insulin cells are protected; and all medicinal ingredients are extracted from natural products, so that the medicament is free from toxic and side effects.

A precursor medicine targetting to kidney is composed of the low-molecular protein chosen from lysozyme, insulin, cytochrome C and pepetide suppressing enzyme or its polypeptide fragment, and the extract of common threewingnut root or its derivative, or glucocorticoid. It can be used as the immune depressant for treating renal disease, or the medicines for treating the rejection reaction and nephritis.

The invention belongs to the technical field of medicine, and discloses a piolitazone hydrochloride p-aminosalicylic acid eutectic crystal, a preparation method, a pharmaceutical composition and application thereof, specifically a piolitazone hydrochloride and p-aminosalicylic acid eutectic crystal solid substance state, a preparation method of a piolitazone hydrochloride and p-aminosalicylic acid eutectic crystal solid substance sample, and application of the piolitazone hydrochloride and p-aminosalicylic acid eutectic crystal substance as an active ingredient in peparation of drugs for reducing blood sugar and blood fat and relieving or preventing diabetic nephropathy and insulin cell degeneration.